Group 1 - As of January 31, 2026, 1,714 out of 2,886 companies in the Shenzhen market have pre-disclosed their 2025 performance, representing 59.39% of the total companies and 48.48% of the market capitalization [1] - Among the pre-disclosed companies, 987 are expected to see performance improvement, with 430 companies achieving continuous profitability and year-on-year growth, while 227 companies are expected to turn losses into profits [1] - The top 100 companies by market capitalization in the Shenzhen market that have pre-disclosed their 2025 performance are expected to achieve a combined net profit of approximately 2,056.27 billion yuan, a year-on-year increase of 66.51% [1] Group 2 - In the Shenzhen market, 307 out of 629 newly listed companies under the registration system have pre-disclosed their 2025 performance, with 183 companies expected to be profitable, which is 59.61% of the pre-disclosed companies [2] - The number of companies expected to incur losses is 124, indicating that the proportion of loss-making companies in the registration system may be below 20% [2] - Notably, companies like China Uranium Industry and Jiangbolong are expected to achieve profits exceeding 1 billion yuan [2] Group 3 - In the Shenzhen market, 18 out of 28 industries are expected to report positive net profits, with significant growth in sectors such as machinery and basic chemicals, which are projected to achieve net profits of 84.85 billion yuan and 123.51 billion yuan, respectively [3] - The electronics and communication sectors are expected to see a growth rate exceeding 50% for the second consecutive year, while industries like non-ferrous metals and textiles are expected to turn losses into profits [3] - The non-ferrous metals industry is projected to achieve a net profit of 328.30 billion yuan, indicating a turnaround from previous losses [3] Group 4 - The computer, communication, and electronics sectors in the Shenzhen market are expected to achieve a combined net profit of 760.33 billion yuan, reflecting a year-on-year growth of 155.32% [4] - Within these sectors, the consumer electronics industry is projected to achieve a net profit of 193.85 billion yuan, a growth of 36.11% [4] - The communication equipment sector is expected to see a significant increase in net profit, projected at 240.76 billion yuan, with a year-on-year growth of 212.39% [4]

Group 1 - Company X is currently undergoing auditing and evaluation work [1] - Company Y has not yet received any orders in the "space photovoltaic" sector [1] - Company Z plans to invest 1 billion yuan in the construction of a synthetic biology manufacturing project in Xinjiang [1] Group 2 - Company A has won a 994 million yuan EPC project [1] - Company B's subsidiary has secured a project worth 101 million yuan [1] - Company C's subsidiary is expected to be awarded a project for the total engineering contract of Huahong FAB9B [1] Group 3 - Company D reported a net profit of 177 million yuan for 2025, representing a year-on-year increase of 42.81% [1] - Company E reported a net profit of 34.93 million yuan for 2025, with a year-on-year growth of 30.13% [1] Group 4 - Company F plans to acquire a portion of equity in Company G, which will increase its holding and achieve control [1] - Company H and its subsidiary plan to transfer 80% of the equity in Wuhan Shengchong [1] Group 5 - Company I has completed the repurchase of 875,000 shares [2] - Company J plans to raise no more than 5 billion yuan through a private placement for a 20GWh power battery project [2] - Company K's actual controller is under investigation by the China Securities Regulatory Commission for alleged market manipulation [2]

Group 1: Company Announcements - Minexplosion Optoelectronics (301362.SZ): Audit and evaluation work for Xiazhi Precision is still ongoing [1] - GCL-Poly Energy (002506.SZ): Has not yet received any orders in the "space photovoltaic" sector [1] - Reborn Bio (300871.SZ): Plans to invest 1 billion yuan in the construction of a synthetic biology manufacturing project in Xinjiang [1] - Southeast Network Frame (002135.SZ): Won a 994 million yuan EPC project [1] - Reborn Bio (300871.SZ): Company and its controlling subsidiary plan to transfer 80% equity of Wuhan Shengchong [1] - Yingjixin (688209.SH): Reported a net profit of 177 million yuan for 2025, a year-on-year increase of 42.81% [1] - Bojie Co., Ltd. (002975.SZ): Completed the repurchase of 875,000 shares [1] - Zhonghuan Hailu (301040.SZ): Jianghai Machinery plans to reduce its holdings by no more than 3% [1] - Guoxuan High-Tech (002074.SZ): Plans to raise no more than 5 billion yuan for a 20GWh power battery project [1] - Beikong Ecological (605069.SH): Signed a strategic cooperation agreement with the People's Government of Miyun District, Beijing [1] Group 2: Performance Reports - Hengwei Technology (603496.SH): Reported a net profit of 34.93 million yuan for 2025, a year-on-year increase of 30.13% [1]

Core Viewpoint - The company is investing 1 billion yuan in a synthetic biology manufacturing project to enhance production capacity, improve efficiency, and maintain market competitiveness [1] Group 1: Investment and Project Details - The project will be constructed in three phases, funded entirely by the company's own resources [1] - The investment aims to address production capacity and efficiency bottlenecks, as existing production lines are insufficient to meet market demand [1] Group 2: Strategic Objectives - The project will strengthen the company's technological leadership by introducing advanced, energy-efficient, and highly automated production equipment [1] - The initiative is part of a core strategy to control costs, particularly in energy consumption, labor, and maintenance, by utilizing automated systems and optimizing site selection in Xinjiang [1]

Core Viewpoint - The company is investing 1 billion yuan in a synthetic biology manufacturing project to enhance production capacity, improve efficiency, and maintain market competitiveness [1] Group 1: Investment and Project Details - The project will be constructed in three phases, funded entirely by the company's own resources [1] - The investment aims to address production capacity and efficiency bottlenecks, as existing production lines are insufficient to meet market demand [1] Group 2: Strategic Objectives - The project will strengthen the company's technological leadership by introducing advanced, energy-efficient, and highly automated production equipment [1] - The initiative is part of a core strategy to control costs, particularly in energy consumption, labor, and maintenance, by optimizing production processes and reducing operational costs [1]

Core Viewpoint - The company Huisheng Biological (300871.SZ) has disclosed a draft for its 2026 employee stock ownership plan, aiming to raise a total of up to RMB 3.081 million [1] Group 1: Employee Stock Ownership Plan - The plan will involve a maximum of 14 participants, with each unit of subscription priced at RMB 1.00, leading to a total cap of 3.081 million units [1] - The shares for the employee stock ownership plan will be sourced from the company's repurchased A-share common stock held in a dedicated securities account [1] - The total number of shares to be transferred under the plan will not exceed 205,400 shares, representing 0.10% of the company's total equity as of the announcement date [1]

Core Viewpoint - The company is expanding its online sales channels for pet pharmaceuticals by transferring 80% of its stake in Wuhan Shengchong Technology Co., Ltd. to Wuhan Xingzhishang Technology Partnership (Limited Partnership) for a total price of RMB 5.52 million [1] Group 1 - The transaction involves Wuhan Kaisheng Biological Technology Co., Ltd. and its subsidiary Wuhan Petry Biological Technology Co., Ltd. [1] - The board of directors has authorized the management to handle all matters related to this transaction, including negotiation, execution, signing of contracts, and business registration changes [1]

Core Viewpoint - The company, Reborn Bio (300871.SZ), has announced an employee stock ownership plan (ESOP) for 2026, aiming to raise a total of up to RMB 3.081 million [1] Summary by Relevant Sections Employee Stock Ownership Plan - The ESOP intends to raise funds not exceeding RMB 3.081 million, with each unit priced at RMB 1.00, and a maximum of 3.081 million units available for subscription [1] - Funding sources for the ESOP will include employees' legal salaries, self-raised funds, and other legally permitted means, with no financial assistance such as loans or guarantees provided by the company to participants [1] - The shares for the ESOP will be sourced from the company's repurchased A-share common stock held in a dedicated securities account [1] Approval and Transaction Method - The ESOP will be subject to approval by the company's shareholders' meeting and will be transferred through legally permitted methods such as non-trading transfers [1] - Upon approval, the ESOP will acquire shares at a price of RMB 15.00 per share from the company's repurchased stock [1]

Core Viewpoint - The company, Wuhan Huaneng Biological Technology Co., Ltd., has approved an investment plan for a synthetic biology manufacturing project in Xinjiang to meet market demand for its core products and enhance production capacity and efficiency [1] Investment Details - The total investment for the Xinjiang synthetic biology manufacturing project is set at 1 billion yuan, which will be financed through the company's own funds [1] - The project will be constructed in three phases: - Phase 1 will focus on building a production workshop for veterinary raw materials and supporting public engineering systems, along with a drying workshop for microbial residues - Phase 2 will involve adding new processing equipment to the existing workshop to expand production capacity - Phase 3 will see the construction of a new production line on reserved land to accommodate the production of new products [1]

证券代码：300871 证券简称：回盛生物 公告编号：2026-007 武汉回盛生物科技股份有限公司 关于注销回购专用证券账户部分股份的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 武汉回盛生物科技股份有限公司（以下简称"公司"）于 2026 年 2 月 4 日召开的第四届董事会第四次会议审议通过了《关于注销回购专用证券账户部 分股份的议案》，同意公司注销回购专用证券账户中的部分股份，并相应减少 注册资本。该事项尚需提交公司 2026 年第一次临时股东会审议，现将相关情 况公告如下： 一、回购股份方案及实施情况 公司于 2022 年 4 月 22 日召开的第二届董事会第二十四次会议和第二届监 事会第二十一次会议分别审议通过了《关于回购公司股份方案的议案》，同意 公司使用不低于人民币 5,000.00 万元（含）且不超过 10,000.00 万元（含）的 自有资金，以集中竞价交易的方式回购公司部分股份，用于实施股权激励计划 或员工持股计划。具体内容详见公司在巨潮资讯网（www.cninfo.com.cn）上披 露的《关于回购公司股份方案的公告》（公告编号 ...